只使用免费官方源：SEC Forms 3/4/5 结构化内部人申报，以及 FINRA Consolidated NMS 场外卖空成交量。 两类数据均保留来源边界，不转写成买卖建议。
SEC 已完成季度 Forms 3/4/5 结构化历史基线 + EDGAR 当前季度 Form 4 增量；个股卡片仅展示当前自然季度的非衍生证券买卖代码 P/S（公开市场或私下交易），成交金额由股数 × 每股价格计算。
官方数据说明| 2026-06-23 2026-06-25 | AVTX Avalo Therapeutics, Inc. | Doyle Mittie Officer · Chief Medical Officer | 卖出（S） | 1,450 | US$18.00 | US$26,100.00 | 51,776 | SEC |
| 2026-05-28 2026-06-01 | AVTX Avalo Therapeutics, Inc. | Doyle Mittie Officer · Chief Medical Officer | 卖出（S） | 679 | US$16.00 | US$10,864.00 | 47,122 | SEC |
| 2026-05-15 2026-05-19 | AVTX Avalo Therapeutics, Inc. | Doyle Mittie Officer · Chief Medical Officer | 卖出（S） | 3,000 | US$18.76 | US$56,280.00 | 3,622 | SEC |
| 2026-05-07 2026-05-11 | AVTX Avalo Therapeutics, Inc. | Sullivan Christopher Ryan Officer · Chief Financial Officer | 卖出（S） | 18,606 | US$24.12 | US$448,776.72 | 423 | SEC |
| 2026-05-06 2026-05-07 | AVTX Avalo Therapeutics, Inc. | VARKI PAUL Officer · Chief Legal Officer | 卖出（S） | 37,375 | US$18.91 | US$706,761.25 | 41,322 | SEC |
| 2026-05-06 2026-05-07 | AVTX Avalo Therapeutics, Inc. | VARKI PAUL Officer · Chief Legal Officer | 卖出（S） | 5,196 | US$19.78 | US$102,776.88 | 36,126 | SEC |
| 2026-05-06 2026-05-07 | AVTX Avalo Therapeutics, Inc. | VARKI PAUL Officer · Chief Legal Officer | 卖出（S） | 9,253 | US$22.70 | US$210,043.10 | 4,034 | SEC |
| 2026-05-06 2026-05-07 | AVTX Avalo Therapeutics, Inc. | VARKI PAUL Officer · Chief Legal Officer | 卖出（S） | 400 | US$23.71 | US$9,484.00 | 3,634 | SEC |
| 2026-05-06 2026-05-07 | AVTX Avalo Therapeutics, Inc. | VARKI PAUL Officer · Chief Legal Officer | 卖出（S） | 22,839 | US$21.22 | US$484,643.58 | 13,287 | SEC |
| 2026-05-06 2026-05-07 | AVTX Avalo Therapeutics, Inc. | Chan Mitchell Director | 卖出（S） | 3,167 | US$22.88 | US$72,460.96 | 3,166 | SEC |
| 2026-05-06 2026-05-07 | AVTX Avalo Therapeutics, Inc. | Sullivan Christopher Ryan Officer · Chief Financial Officer | 卖出（S） | 9,219 | US$21.37 | US$197,010.03 | 9,323 | SEC |
| 2026-05-06 2026-05-07 | AVTX Avalo Therapeutics, Inc. | Sullivan Christopher Ryan Officer · Chief Financial Officer | 卖出（S） | 2,700 | US$20.76 | US$56,052.00 | 18,542 | SEC |
| 2026-05-06 2026-05-07 | AVTX Avalo Therapeutics, Inc. | Sullivan Christopher Ryan Officer · Chief Financial Officer | 卖出（S） | 12,347 | US$19.28 | US$238,050.16 | 21,242 | SEC |
| 2026-05-06 2026-05-07 | AVTX Avalo Therapeutics, Inc. | Sullivan Christopher Ryan Officer · Chief Financial Officer | 卖出（S） | 8,900 | US$22.57 | US$200,873.00 | 423 | SEC |
| 2026-05-06 2026-05-07 | AVTX Avalo Therapeutics, Inc. | Sullivan Christopher Ryan Officer · Chief Financial Officer | 卖出（S） | 13,834 | US$18.55 | US$256,620.70 | 33,589 | SEC |
| 2026-05-06 2026-05-07 | AVTX Avalo Therapeutics, Inc. | Doyle Mittie Officer · Chief Medical Officer | 卖出（S） | 19,015 | US$22.41 | US$426,126.15 | 13,680 | SEC |
| 2026-05-06 2026-05-07 | AVTX Avalo Therapeutics, Inc. | Doyle Mittie Officer · Chief Medical Officer | 卖出（S） | 44,944 | US$21.20 | US$952,812.80 | 32,695 | SEC |
| 2026-05-06 2026-05-07 | AVTX Avalo Therapeutics, Inc. | Doyle Mittie Officer · Chief Medical Officer | 卖出（S） | 5,000 | US$19.65 | US$98,250.00 | 77,639 | SEC |
| 2026-05-06 2026-05-07 | AVTX Avalo Therapeutics, Inc. | Doyle Mittie Officer · Chief Medical Officer | 卖出（S） | 27,538 | US$18.03 | US$496,510.14 | 82,639 | SEC |
| 2026-05-06 2026-05-07 | AVTX Avalo Therapeutics, Inc. | Doyle Mittie Officer · Chief Medical Officer | 卖出（S） | 10,058 | US$22.88 | US$230,127.04 | 3,622 | SEC |
| 2026-05-05 2026-05-07 | AVTX Avalo Therapeutics, Inc. | Doyle Mittie Officer · Chief Medical Officer | 卖出（S） | 1,679 | US$16.00 | US$26,864.00 | 3,622 | SEC |
| 2026-05-01 2026-05-05 | AVLN Avalyn Pharma Inc. | Novo Holdings A/S TenPercentOwner | 买入（P） | 555,555 | US$18.00 | US$1000万 | 3,883,289 | SEC |
| 2026-05-01 2026-05-01 | AVLN Avalyn Pharma Inc. | George Simeon TenPercentOwner | 买入（P） | 277,777 | US$18.00 | US$500万 | 1,122,087 | SEC |
| 2026-05-01 2026-05-01 | AVLN Avalyn Pharma Inc. | SR ONE CAPITAL MANAGEMENT, LLC TenPercentOwner | 买入（P） | 277,777 | US$18.00 | US$500万 | 1,122,087 | SEC |
| 2026-05-01 2026-05-01 | AVLN Avalyn Pharma Inc. | George Simeon TenPercentOwner | 买入（P） | 277,778 | US$18.00 | US$500万 | 2,186,562 | SEC |
| 2026-05-01 2026-05-01 | AVLN Avalyn Pharma Inc. | SR ONE CAPITAL MANAGEMENT, LLC TenPercentOwner | 买入（P） | 277,778 | US$18.00 | US$500万 | 2,186,562 | SEC |
| 2026-05-01 2026-05-01 | AVLN Avalyn Pharma Inc. | Carroll Jill Director | 买入（P） | 277,778 | US$18.00 | US$500万 | 2,186,562 | SEC |
| 2026-04-30 2026-05-01 | AVTX Avalo Therapeutics, Inc. | Sullivan Christopher Ryan Officer · Chief Financial Officer | 卖出（S） | 8,457 | US$13.23 | US$111,886.11 | 423 | SEC |
| 2026-04-29 2026-05-01 | AVTX Avalo Therapeutics, Inc. | Sullivan Christopher Ryan Officer · Chief Financial Officer | 卖出（S） | 8,458 | US$13.09 | US$110,715.22 | 8,880 | SEC |
| 2026-04-06 2026-04-08 | AVTX Avalo Therapeutics, Inc. | Doyle Mittie Officer · Chief Medical Officer | 卖出（S） | 3,970 | US$18.01 | US$71,499.70 | 3,622 | SEC |
| 2026-04-02 2026-04-03 | AVTX Avalo Therapeutics, Inc. | Sullivan Christopher Ryan Officer · Chief Financial Officer | 卖出（S） | 1,780 | US$17.57 | US$31,274.60 | 17,338 | SEC |
| 2026-04-02 2026-04-03 | AVTX Avalo Therapeutics, Inc. | Sullivan Christopher Ryan Officer · Chief Financial Officer | 卖出（S） | 6,200 | US$17.02 | US$105,524.00 | 19,118 | SEC |
| 2026-04-01 2026-04-03 | AVTX Avalo Therapeutics, Inc. | Sullivan Christopher Ryan Officer · Chief Financial Officer | 卖出（S） | 7,479 | US$16.83 | US$125,871.57 | 25,318 | SEC |
| 2026-04-01 2026-04-03 | AVTX Avalo Therapeutics, Inc. | Sullivan Christopher Ryan Officer · Chief Financial Officer | 卖出（S） | 500 | US$15.86 | US$7,930.00 | 32,797 | SEC |
| 2026-04-01 2026-04-03 | AVTX Avalo Therapeutics, Inc. | Doyle Mittie Officer · Chief Medical Officer | 卖出（S） | 679 | US$16.00 | US$10,864.00 | 3,622 | SEC |
| 2026-03-31 2026-04-01 | PGC PEAPACK GLADSTONE FINANCIAL CORP | Cavallaro Frank A. Officer · SEVP & Chief Financial Officer | 买入（P） | 2,889.84 | US$34.95 | US$100,999.91 | 14,713.84 | SEC |
| 2026-03-27 2026-04-13 | ABEV AMBEV S.A. | Cavalcanti de Lacerda Eduardo Braga Officer · See Remarks | 卖出（S） | 152,386 | US$2.85 | US$434,300.10 | 223,340 | SEC |
| 代码 | 卖空成交量 | 豁免卖空量 | 场外总成交量 | 卖空量占比 | 报告设施 |
|---|---|---|---|---|---|
| AVAL | 12,607.8509 | 0 | 33,777.8957 | 37.33% | B, Q, N |